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a b s t r a c t
Objective: To determine the prevalence of patients with type 1 diabetes mellitus who meet
the glycemic and cardiovascular (CV) risk factors goals and the frequency of screening for
diabetic complications in Brazil according to the American Diabetes Association guidelines.
Research design and methods: This was a cross-sectional, multicenter study conducted
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Results: Systolic blood pressure was at goal in 40.3% and diastolic blood pressure was at goal
in 26.6% of hypertensive patients. LDL cholesterol and HbA1c were at the goal in 45.2% and
13.2% of the patients, respectively. Overweight was presented in 25.6% and obesity in 6.9%.
Among those with more than 5 years of disease, screening for retinopathy was performed in
the preceding year in 70.1%. Nephropathy and feet complications were screened in 63.1%
and 65.1%, respectively.
Conclusions: The majority of patients did not meet metabolic control goals and a substantial
proportion was not screened for diabetic complications. These issues may increase the risk
of chronic complications and negatively impact public health.
# 2012 Elsevier Ireland Ltd. 
Keywords:
Type 1 diabetes
Glycemic control
Cardiovascular risk factors
Chronic complications
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 9 7 ( 2 0 1 2 ) 6 3 – 7 064
Open access under the Elsevier OA license.1. Introduction
The incidence of type 1 diabetes mellitus (T1DM) is increasing
in developed [1,2] and developing countries, including Brazil
[3]. T1DM carries a great risk of morbidity and mortality due to
the microvascular and macrovascular complications that
result in a lower quality of life and life expectancy [4].
There is strong evidence to support the efficacy and cost-
effectiveness of programs that help improve glycemic control
and reduce several cardiovascular (CV) risk factors in patients
with T1DM and type 2 diabetes mellitus (T2DM) [5,6]. The
Diabetes Control and Complications Trial (DCCT) showed that
the effective control of diabetes contributes to decrease the
risk of developing chronic microvascular complications
despite the difficulty of achieving the recommended level of
glycemic control even with multiple daily insulin injections or
insulin pump therapy [5].
Additionally, the DCCT/Epidemiology of Diabetes Inter-
ventions and Complications Study showed that patients in the
intensive treatment group during the DCCT had lower rates of
CV events at the 11th year than patients assigned to the
conventional treatment group, even with similar levels of
HbA1c, LDL cholesterol, HDL cholesterol and triglycerides [7].
These findings suggest that early intensive glycemic control
has long-term benefits on the rate of adverse CV outcomes.
However, there is a gap between the recommendations of
the guidelines to control blood pressure, glycemic and lipid
levels and the values described in most observational studies
of T1DM [7,8] and T2DM [9]. There is also a gap between the
recommended and reported frequencies of screening for
chronic complications. Additionally, these gaps substantially
increase the overall risk of developing microvascular and
macrovascular complications. These findings underscore the
difficulty of treating these patients and emphasize the need
for improved clinical care quality. Consequently, diabetes has
emerged as a major health problem in societies where non-
communicable diseases are the most common causes of
disabilities and death, and it requires large expenditures
because of its increasing direct and indirect costs [10].
Our study aimed to determine the degree of glycemic
control, the presence of CV risk factors and the frequency of
screening for T1DM-related chronic complications in Brazil
using the ADA guidelines and to evaluate health care
practices, disease management and the frequency with which
the recommended treatment goals were met.2. Research design and methods
This study was an observational, cross-sectional, multicenter
study conducted between December 2008 and December 2010
in 28 public clinics of the secondary and tertiary care level
located in 20 cities in four Brazilian geographic regions (north/
northeast, mid-west, southeast and south). All patients
received health care from the National Brazilian Health Care
System (NBHCS). To be eligible, the participant centers had to
have a diabetes clinic with at least one endocrinologist.
Overall, 31 public clinics were identified and invited to
participate. A short questionnaire was sent to the clinics to
acquire information on the characteristics of the patient
population, especially the number of T1DM patients under
routine care; three clinics did not send back the answered
questionnaire until the implementation of the study and were
not included. The number of patients enrolled in each region
was calculated based on the estimated prevalence of T1DM in
Brazil and the population density of each geographic region.
As patients with T1DM usually are treated at secondary or
tertiary centers in our country, primary care centers were not
included in the study. Each clinic provided data from at least
50 consecutive attended outpatients with an initial diagnosis
of T1DM who regularly attended the clinic. The inclusion
criteria, which were determined from the standardized
medical chart review form data, included the diagnosis of
T1DM by a physician based on typical clinical presentation,
which means a variable degree of weight loss, polyuria,
polydipsia and polyphagia and the need to use insulin
continuously since the diagnosis without interruption and
medical follow-up for at least six months at the respective
center. All patients were diagnosed between 1960 and 2010.
Demographic and educational data as well as economic status
were also obtained. Patients with diabetes for less than five
years in duration were not included in the analysis of diabetic
complications (n = 200, 11.3%). As listed in Appendix 1, each
local center’s ethics committee approved the study. The
Brazilian Diabetes Society (BDS) coordinated the study by
monitoring and reviewing all study-related documents and
approving all amendments and publications. The chart form
was reviewed by leading diabetologists in Brazil before the
final approval. Each center had a coordinator who was trained
on how to perform and analyze data obtained from the charts.
The chart reviews were finalized in 2008, after which the study
was implemented.
Table 1 – Clinical and demographic data of the study
population.
Variable
Age, y 30.3  9.7
Gender, F (%) 1008 (56.8)
Age at diagnosis, y (%)
0–4.9 128 (7.2)
5–9.9 269 (15.2)
10–14.9 448 (25.3)
15–19.9 414 (23.3)
20–29.9 393 (22.2)
30 122 (6.9)
Ethnicity, n (%)
Caucasian 1,015 (57.2)
Non-Caucasiana 759 (42.8)
Economic status
High 183 (10.3)
Medium 497 (28)
Low 608 (34.3)
Very low 486 (27.4)
Duration of diabetes, y 14.3  8.5
Geographic region (%)
Southeast 704 (39.7)
North/Northeast 527 (29.7)
South 424 (23.9)
Middle West 119 (6.7)
Treatment of diabetes, n (%)
Insulin
Intermediate acting 289 (16.3)
Long acting 23 (1.3)
Pump 26 (1.5)
Intermediate/long plus short acting 1434 (80.8)
Short acting shots 3/day 864 (60.2)
SBGM 1482 (83.5)
Specialist visits in the prior, y 1750 (98.6)
Data are presented as the means (SD) and n (%). y, year; F, female;
SBGM, self blood glucose monitoring.
a African-Brazilians, Mulattos, Asians, Native Indians.
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view during a clinical visit: current age, age at diagnosis,
duration of diabetes (years), height (m) and weight (kg), blood
pressure (systolic and diastolic in mmHg), modality of
treatment for diabetes and its comorbidities, frequency of
self-blood glucose monitoring (SBGM) and smoking status. The
levels of HbA1c, fasting (FPG) and 2 h-post-breakfast glucose
(PPG), fasting total cholesterol, LDL cholesterol, HDL choles-
terol and triglycerides recorded in the last visit to the clinic
were obtained from the medical records. It was also deter-
mined whether screening for retinopathy by fundoscopy and
nephropathy by microalbuminuria and a feet examination
had been completed in patients with diabetes for more than
five years in duration within one year of the study assessment
[11].
The ADA goals for good metabolic and clinical control [11]
that were adopted by the Brazilian Type 1 Diabetes Study
Group included the following: HbA1c < 7%, systolic blood
pressure (sBP) < 130 mmHg, diastolic blood pressure
(dBP) < 80 mmHg, body mass index (BMI) < 25 kg/m2,
FPG < 7.2 mmol/l (130 mg/dl), PPG < 10 mmol/l (180 mg/dl),
total cholesterol < 5.2 mmol/l (200 mg/dl), HDL cholester-
ol > 1.1 mmol/l for men (40 mg/dl) and >1.3 mmol/l (50 mg/
dl) for women, LDL cholesterol < 2.6 mmol/l (100 mg/dl), non-
HDL cholesterol < 3.30 mmol/l (130 mg/dl) and triglyceri-
des < 1.7 mmol/l (150 mg/dl/l).
Hypertension was defined as a sBP  140 mmHg and/or
dBP  90 mmHg obtained during the last visit [11] or self-
reported hypertension. HbA1c values and the methods used to
measure it were collected from the medical charts. In 1678
patients (94.6%), HbA1c was measured using methods certified
by the National Glycohemoglobin Standardization Program
(NGSP), including high-performance liquid chromatography in
968 patients (54.6%) and turbidimetry in 710 patients (40.0%).
HbA1c levels that were determined using methods not
certified by the NGSP, and missing data were excluded from
the analysis of glycemic control (n = 239, 13.5%). Plasma
glucose, triglycerides, HDL and total cholesterol were mea-
sured using enzymatic techniques. LDL level was calculated
using Friedewald’s equation [12]. BMI (kg/m2) was determined
by dividing the weight (kg) by the height squared (m2). Current
smoking was defined as a patient smoking more than one
cigarette per day at the time of the interview. Written
informed consent for the study was obtained from all patients.
3. Statistical analysis
The study sample aimed to represent the distribution of T1DM
cases across the various regions of Brazil. The proportion of
cases in each region was estimated using the overall
population distribution reported in the 2000 Brazilian Institute
of Geography and Statistics Census (IBGE) (38.8%, 31.7%, 23.0%
and 6.6% in the southeast, north/northeast, south and mid-
west regions, respectively) [13]. This was combined with
national estimates of the prevalence of diabetes from the
survey on the topic performed in 1988 to determine the
minimum number of patients to sample in each region [14]. In
this survey, the estimated prevalence of diabetes was 7.6% in
people 30–69 years in age, and the prevalence of self-reporteddiabetes in subjects younger than 30 years was 0.1%; the
majority of the subjects younger than 30 years were assumed
to have T1DM. Concerning the recruitment, each region of the
country enrolled >95% of the estimated number of patients.
Economic status was defined according to the Brazilian
Economic Classification Criteria. This classification also
considers education level, which is categorized as illiterate/
incomplete primary education, complete primary education/
incomplete secondary education, complete secondary educa-
tion/incomplete high school, complete high school/some
college and complete college education. For this analysis,
the following classes of economic status were considered:
high, middle, low and very low [15].
Data are presented as the mean (SD) for continuous
variables and as counts (relative frequencies) for discrete
variables. Comparisons between genders were performed
using independent two-sided t-tests or ANOVA for continuous
variables VA and two-sided z-tests for discrete variables with a
normal approximation to the binomial distribution. Due to the
number of variables tested sequentially, p-values were
adjusted using the Sida`k [16] procedure to control for type I
errors. A Pearson’s correlation coefficient was calculated
where indicated. All analyses were performed using R
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the global significance threshold was 0.05.
4. Results
Clinical and demographic data from the study population are
shown in Table 1. The majority of our patients had less than 30
years, n = 1077, (60.7%) and had a duration of diabetes as
follow: <1–5 years, n = 128 (7.2%); 5–10 years, n = 269 (15.2%);
10–15 years, n = 448 (25.3%) and 15 years, 929 (52.4%). Overall,
481 (27.1%) were treated at the secondary care level and 1293
(72.9%) at the tertiary care level. The average follow-up time in
the participating centers was 8.5  6.9 years.
The most commonly used therapeutic regimen was the
combination of intermediate-acting or long-acting insulin
plus short-acting insulin (80.8% of patients). Three or more
daily injections of short-acting insulin and three or more
measurements of SBGM were reported by 60.2% and 83.5% of
patients, respectively. There was no difference in the overall
prevalence (85.2 vs. 82.9%, p = 0.2) or number of daily
frequency of SBGM (3.2  2.2 vs. 3.4  2.0; p = 0.08) between
women and men. A weak negative correlation between HbA1c
levels and the daily frequency of SBGM was observed
(r = 0.08; p = 0.001).
Clinical and laboratory data, as well as the proportions of
patients who underwent clinical and biochemical evaluation
and who reached the ADA criteria for good control, are shown
in Table 2. HbA1c levels 7% and <9% were found in 643
(40.2%) and HbA1c levels 9% in 682 (42.9%) patients. The
means of HbA1c levels were related to economic status. HigherTable 2 – Evaluation of glycemic control and cardiovascular-re
complications in the year prior to the study.
Variable Frequency of
complete records, n (%
Glycemic control
HbA1c (%) 1535 (86.5) 
FPG (mmol/l) 1658 (93.7) 
2h-PPG (mmol/l) 893 (50.3) 
IMC (kg/m2) 1744 (98.3) 
Cardiovascular risk factors
sBP (mmHg) 1769 (99.7) 
dBP (mmHg) 1768 (99.7) 
Total cholesterol (mmol/l) 1591 (89.9) 
Triglycerides (mmol/l) 1555 (87.6) 
HDL cholesterol (mmol/l) 1545 (87.3) 
LDL cholesterol (mmol/l) 1432 (80.9) 
Non-HDL cholesterol (mmol/l) 1549 (87.3) 
Smoking status (y), n (%) 1774 (100) 
Chronic complications
Feet examination 1574 (89.7) 
Fundoscopy 1774 (100) 
Urine albumin 1774 (100) 
Data are presented as n (%) or the mean (SD).
a For this analysis, we considered the following goals of the American 
HbA1c < 7.0%; BMI < 25 kg/m2; sBP < 130 mmHg; dBP < 80 mmHg; FPG < 
ol < 5.2 mmol/l (200 mg/dl), HDL cholesterol > 1.1 mmol/l (40 mg/dl for m
mmol/l (100 mg/dl), non-HDL cholesterol < 3.30 mmol/l (130 mg/dl) and t
b Number (%) of current smokers.
c Number of patients (%) evaluated for chronic complications.HbA1c levels were observed in patients from very low
economic status (9.4  2.4%) in comparison to patients from
low (9.0  2.2%), medium (9.1  2.1%) and high economic
status (8.7  2.0%), p < 0.001. The goal for HbA1c was reached
by 206 patients (11.6%). More patients from high economic
status reached the goal for HbA1c (19%) in comparison to
patients from medium (12%), low (12%) and very low economic
status (13.7%) but this data was not statistically significant.
Overweight was observed in 341 (20.2%) and obesity in 156
(9.2%) participants. A current smoking status was reported by
129 (7.3%) patients. Four hundred eighty-two (27.2%) patients
used anti-hypertensive agents, and of these, 160 (33.3%) were
at their target levels for both sBP and dBP. Hypertension was
observed in 560 (31.6%) of the patients with 319 (57%) of them
under treatment. Among the hypertensive patients, 226
(40.3%) and 149 (20.2%) were within the target for sBP and
dBP respectively. Overall, 73 (23%) of the patients with
hypertension and using anti-hypertensive agents were within
the targets for both sBP and dBP. Considering the pooled
studied population, 355 (20.1%) patients were not at their goals
for sBP and dBP, and 168 (46.8%) of them were not using anti-
hypertensive agents. Patients with criterion for screening of
chronic diabetes-related complications, at goal of HbA1c and
with available urine albumin concentration (n = 97) that had
hypertension had a higher urine albumin concentration than
patients without hypertension, respectively [13.4 mg/ml (0.22–
784.0 mg/ml) vs. 5.7 (0.1–784 mg/ml, p = 0.01).
Most patients were at their total cholesterol and triglycer-
ides goals (72.5% and 77.4%, respectively), but only 45.5% of
them reached their LDL cholesterol goals. Statins were used by
263 (14.8%) patients, and 111 of them (42.2%) were within thelated risk factors and screening for chronic diabetes
)
Mean (SD)
or n (%)
Patients at goala,
or evaluatedc, n (%)
9.1 (2.23) 206 (11.6)
9.7 (5.7) 498 (30)
12.8 (7.1) 340 (38.4)
23.8 (3.80) 1195 (67.4)
118.5 (16.75) 1344 (75.8)
75.8 (11.06) 926 (52.2)
4.5 (1.1) 1267 (79.6)
1.1 (0.8) 1353 (87)
1.4 (0.4) 1020 (66)
2.6 (0.9) 808 (52.7)
3.1 (1.0) 1016 (65.3)
129 (7.3)b
– 1154 (65.1)
– 1115 (70.1)
– 993 (63.1)
Diabetes Association (ADA) for patients with measured risk factors:
7.2 mmol/l (130 mg/dl), PPG < 10 mmol/l (180 mg/dl), total cholester-
en) and >1.3 mmol/l (50 mg/dl) for women, LDL cholesterol < 2.6 m-
riglycerides < 1.7 mmol/l (150 mg/dl/l).
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had LDL cholesterol levels above their target levels and were
not receiving treatment.
Women had higher total cholesterol [4.7  1.1 mmol/l
(180.6  43.9 mg/dl) vs. 4.3  1 mmol/l (166.4  39.9 mg/dl);
p < 0.001], non-HDL cholesterol [3.2  1.1 mmol/l
(123.4  41.7 mg/dl) vs. 3.0  1.0 mmol/l (116.8  38.4 mg/dl);
p = 0.04] and LDL cholesterol [2.7  0.9 mmol/l
(104.5  35.6 mg/dl) vs. 2.5  0.9 mmol/l (98.5  33.2 mg/dl);
p = 0.02] than men, and more women were treated with
statins (17.1% vs. 11.9%, p = 0.02) compared with men.
Men had a higher sBP than women (120.3  16.4 vs.
117.1  16.9 mmHg; p = 0.002). Similar proportions of women
(23.6%) and men (24.2%) had hypertension and were at their
BMI (66.5% vs. 68.4%), HbA1c (11.4% vs. 11.8%), FPG (27% vs.
22.5%), sBP (78.1% vs. 72.4%), dBP (54.9% vs. 48.5%), total
cholesterol (68.4% vs. 77.9%), triglycerides (75.9% vs. 79.2%),
LDL cholesterol (43.6 vs. 48%) and non-HDL cholesterol goals
(56% vs. 58.8%; p > 0.05 for all comparisons). More men than
women were at their HDL cholesterol goals (74.8% vs. 51.9%;
p = 0.01).
Patients treated at tertiary centers compared to those
treated to secondary were older (30.7  10.1 vs. 29.2  8.5
years, p = 0.001) and had a longer duration of diabetes (15  8.6
vs. 12.1  7.7 years, p = 0.001). Regarding the quality of care,
more patients treated at secondary centers were within the
targets for BMI (73.2% vs. 65.1%, p = 0.001), and more patients
treated at tertiary centers reached the targets for dBP (56.8 vs.
50.7%, p = 0.02) and LDL cholesterol (54.9% vs. 47.8%, p = 0.01).
The other parameters were not significantly different between
patients treated at secondary and tertiary centers.
Furthermore, 42%, 37.1% and 44% patients did not have
their feet, eyes and urine albumin excretion evaluated,
respectively within one year of the study assessment.
Smoking was reported by 7.3% of our patients, more
frequently in men than women (9.1 vs. 4.8%, respectively;
p = 0.01). These data are shown in Table 2. The frequency of
screening for diabetes complications was not related to
gender, but it was related to the level of care. More patients
treated at tertiary care centers had feet examinations (76.4 vs.
64.4%, p < 0.001) and urine albumin excretion evaluations in
the year prior to the study (65.1 vs. 57.2%, p = 0.004).
5. Discussion
The Brazilian Type 1 Diabetes Study Group is an ongoing
survey that analyzes the demographic, clinical and socioeco-
nomic data of T1DM patients receiving treatment in public
clinics in Brazil.
In this study, we found variability in the proportion of
patients reaching their targets depending on the parameters
evaluated. For most patients, blood pressure levels were
within their goals. However, glycemic control was unsatisfac-
tory in approximately 89% of our patients. Overweight was an
important issue in one-third of the study patients. Addition-
ally, approximately half of the patients were not screened for
diabetes complications in the previous year. It is important to
mention that all of the patients were treated by an
endocrinologist in the secondary and tertiary care settings.Our findings are alarming in several ways, and the data
suggest that it is necessary and urgent to develop another
health care model for T1DM in Brazil.
The treatment of diabetes in Brazil is guided by the BDS,
whose recommendations are essentially the same as those of
the ADA. Considering that diabetes treatment in public clinics
is financed by the NBHCS, our data show that factors other
than medical recommendations likely interfere with diabetes
care in Brazil, especially social and economic factors. The
latter fact could be associated with the low or very low
economic status found in 61.7% of our patients. It is important
to emphasize that economic status in Brazil also takes in
account educational level.
Although the ADA recommends at least three HbA1c
measurements per year, approximately 13% of patients had
received no HbA1c measurements in the prior year because
their health care center did not always offer this test. However,
among those patients who had undergone HbA1c measure-
ments in the year prior to the study, the average number of
measurements was similar to that of the ADA and BDS
recommendations [11] but widely varied from one to ten per
year. This range indicates that there is no agreement in Brazil
regarding the number of HbA1c measurements routinely
performed to monitor the treatment of a patient with T1DM.
Other factors related to the physician’s interpretation of the
test may explain this discrepancy.
Although most patients had complex therapeutic regimens
and performed SBGM, more than 40% of patients had HbA1c
levels greater than 9%, indicating poor glycemic control. This
supports the weak correlation found between HbA1c levels
and the daily frequency of SBGM, possibly reflecting patient
problems with insulin dose adjustments, difficulties of basal/
bolus balances and poor diabetes health care and education.
Some studies, including ours, did not show an important
association between glycemic control and the frequency of
SBGM [17], although such an association has been observed in
another study [22], but only after educational interventions.
The overall difficulty in achieving glycemic control in T1DM
through routine care is described in many observational
studies worldwide [17–22].
There is compelling evidence that intensive management
of weight, cholesterol and blood pressure is effective in
delaying or preventing microvascular and macrovascular
complications. Although most of our patients reached the
sBP and total cholesterol goals, 40–50% did not reach the dBP,
LDL cholesterol, HDL cholesterol or non-HDL cholesterol goals,
which is similar to the data found in other observational
studies [7,18,23,24,27]. However, our results suggest that an
additional major health issue in T1DM is being overweight or
obese, similar to results found in other populations with T1DM
[7,18,25,26] and in patients with T2DM in Brazil [9].
Although the guidelines recommend aggressive dyslipide-
mia and hypertension treatments in T1DM, fewer than 30% of
our patients were receiving treatment for both clinical
conditions during our study; similar results were described
in Sweden [18]. Only 14.8% of our patients were using statins
for dyslipidemia. Of these patients, fewer than 50% were at
LDL cholesterol goals. Approximately 31.6% of our patients
had hypertension with 57%f of them using antihypertensive
agents, but only 20% of these patients were within their goal
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Diabetes Complications Study used different targets for
blood pressure and LDL cholesterol and demonstrated small
improvements in hypertension and dyslipidemia control,
primarily in younger age groups of T1DM patients over a 10-
year follow-up [23]. When T1DM patients were above their
goal, one study of academic medical centers observed a low
rate of medication management [8]. Considering over-
weight, obesity, hypertension and dyslipidemia as CV risk
factors, we can conclude that our young patients represent a
high-risk group for microvascular and macrovascular
complications of diabetes, as described in other studies
[26–28]. However, in our study, there were fewer T1DM
patients who were current smokers than previously
reported in Europe [18] and the USA [29].
Screening for diabetic complications also did not meet the
recommendations of the ADA guidelines; not all patients had a
documented fundoscopy, and nearly 40% of our patients did
not have a documented feet exam or urine albumin evaluation
in the prior year. These data are in agreement with those of
other studies [8]. It is important to emphasize that urine
albumin evaluation is now regularly performed in 75% of the
public hospitals included in the present study. Concerning the
level of care, more patients who attended tertiary care clinics
compared with secondary centers had had a feet examination
and urine albumin evaluation in the prior year and reached the
targets for dBP and LDL cholesterol. Considering the latter fact,
the differences in age and BMI between both groups may have
accounted for this difference [8,17].
The principal strength of our large sample is that the
included cases are representative of the distribution of T1D in
the diverse young Brazilian population. The study included
patients of a wide range of ethnic groups from all geographic
regions of the country and had a recruitment process with a
uniform, standard protocol in all participating centers.
Several limitations of our study must be addressed. One
limitation was the sample characteristics. Similar to other
studies, we used a clinical definition of T1DM assigned by
physicians that was applicable to all patients. However, as
autoantibodies and C-peptide levels were not measured, some
patients with other types of diabetes may have been included.
Nevertheless, it is important to emphasize that 93.1% of our
patients were diagnosed before 30 years of age, which
reinforces the high probability that they truly had T1DM. All
patients were seen in a public center by a specialist and lived
in large cities; patients who rely on primary care facilities and
live in rural areas may have been overlooked. However, the
latter T1DM patients are the minority of those receiving
treatment in Brazil. Additionally, the recruitment of patients
within each center may have led to a selection bias mainly
concerning age because the majority of our patients are
younger than 30 years. Another limitation is a lack of
standardization for evaluation of HbA1c levels. Although
two different methods to determine HbA1c are used across the
country we still can have different upper limits of normality
for the same method. This variation may have also influenced
our results.
Also, the consideration of self-reported hypertension as a
criterion of its presence may have led to a bias in the diagnosis
of this condition that may also have influenced our results inits prevalence. However, it is important to emphasize that the
primary criteria for the diagnosis of hypertension was the
evaluation of blood pressure levels obtained by medical
evaluation.
In conclusion, sufficient screening for diabetic complica-
tions and the target levels for glycemic control, blood pressure
and lipids are difficult to achieve in patients with T1DM.
Multiple CV risk factors were found in most patients. The
quality of diabetes care must be substantially improved in
Brazil.
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